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Summary
Clinical characteristics
CYLD cutaneous syndrome (CCS) typically manifests in the second or third decade with the appearance of 
multiple skin tumors including cylindromas, spiradenomas, trichoepitheliomas, and rarely, membranous basal 
cell adenoma of the salivary gland. The first tumor typically develops at puberty and tumors progressively 
accumulate through adulthood. Females often have more tumors than males. Tumors typically arise on the scalp 
and face but can also arise on the torso and sun-protected sites, such as the genital and axillary skin. A minority 
of individuals develop salivary gland tumors. Rarely, pulmonary cylindromas can develop in large airways and 
compromise breathing. Although the tumors are usually benign, malignant transformation is recognized.
Diagnosis / testing
The diagnosis of CYLD cutaneous syndrome is established in a proband with multiple skin tumors 
(histologically confirmed cylindromas, spiradenomas, and/or trichoepitheliomas) and/or by identification of a 
germline heterozygous pathogenic variant in CYLD by molecular genetic testing.
Management
Treatment of manifestations: Removal of cylindromas, spiradenomas, and trichoepitheliomas is by conventional 
surgery. Ideally, as much normal scalp and skin should be preserved. "Scalp-sparing" strategies include early 
primary excision with direct skin closure, tumor enucleation followed by direct skin closure, and excision 
followed by secondary intention healing techniques. Hyfrecation or laser ablation of selected small tumors may 
be considered. Mohs micrographic surgery for recurrence of tumors after failure of primary surgical excision 
may have limited benefit. Multidisciplinary team management of tumors that have undergone malignant 
transformation is recommended.
Prevention of primary manifestations: Appropriate precautions against UV-related skin damage are 
recommended.
Author Affiliation: 1 Department of Dermatology, Royal Victoria Infirmary, Newcastle upon Tyne, UK; Email: 
anna.dubois@nhs.net; Email: neil.rajan@ncl.ac.uk.
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Surveillance: Annual or more frequent full skin examination by a dermatologist, with assessment of tumor 
burden and rate of new tumor development, and for signs/symptoms of malignant transformation (rapid tumor 
growth, bleeding, ulceration, or appearance that is different from an affected individual's usual tumors).
Agents/circumstances to avoid: Radiotherapy should be avoided as it causes DNA damage and may result in 
further tumor formation or malignant transformation of existing lesions.
Evaluation of relatives at risk: It is appropriate to clarify the genetic status of apparently asymptomatic older and 
younger at-risk relatives of an affected individual in order to identify as early as possible those who would 
benefit from prompt initiation of treatment and preventive measures.
Genetic counseling
Germline pathogenic variants in CYLD are inherited in an autosomal dominant manner. Most individuals with 
CYLD cutaneous syndrome inherit it from a parent. The degree of severity can vary within families; for example, 
a mildly affected parent may have a more severely affected child or vice versa. Offspring of an individual with 
CYLD cutaneous syndrome have a 50% chance of inheriting the variant. Prenatal testing is possible for 
pregnancies at increased risk if the CYLD pathogenic variant in the family is known; however, requests for 
prenatal diagnosis of later-onset diseases are uncommon and require careful genetic counseling.
Diagnosis
Formal diagnostic criteria for CYLD cutaneous syndrome (CCS) have not been established.
Suggestive Findings
CYLD cutaneous syndrome should be suspected in an individual with the following findings:
• The presence of one or more cylindromas or spiradenomas on the face and scalp, perinasal 
trichoepitheliomas, or a combination of these tumor types in an individual
Cylindromas, spiradenomas, and trichoepitheliomas can be diagnosed clinically but may mimic other skin 
tumors, thus requiring confirmatory skin biopsy.
• A cylindroma or spiradenoma on the scalp or torso incidentally identified during an imaging study (CT, 
MRI, and/or PET scan) [Serra et al 1996, Brown et al 2018a]
• A membranous basal cell adenoma-type salivary gland tumor in an individual with a single cylindroma, 
spiradenoma, or trichoepithelioma
Clinical genetic testing for a germline heterozygous CYLD pathogenic variant should be considered in an 
individual with the following [Dubois et al 2015]:
• Two or more biopsy-confirmed cylindromas, spiradenomas, or trichoepitheliomas
• A single biopsy-confirmed cylindroma, spiradenoma, or trichoepithelioma in the setting of a first-degree 
relative who has any one of these biopsy-confirmed tumors
Establishing the Diagnosis
The diagnosis of CYLD cutaneous syndrome is established in a proband with multiple skin tumors 
(histologically confirmed cylindromas, spiradenomas, and/or trichoepitheliomas) and/or by identification of a 
germline heterozygous pathogenic variant in CYLD by molecular genetic testing [Dubois et al 2015] (see Table 
1).
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When the phenotypic and laboratory findings suggest the diagnosis of CYLD cutaneous syndrome, molecular 
genetic testing approaches include single-gene testing or use of a multigene panel.
Single-gene testing. Sequence analysis of CYLD detects small intragenic deletions/insertions and missense, 
nonsense, and splice site variants; typically, exon or whole-gene deletions/duplications are not detected. Perform 
sequence analysis on a peripheral blood sample first.
• If no pathogenic variant is found, and there is no known family history of this condition, it is possible that 
the proband has mosaicism for a CYLD pathogenic variant.
If mosaicism is suspected, sequence analysis of CYLD can be performed on two or more skin tumors 
[Arefi et al 2019].
• Gene-targeted deletion/duplication analysis to detect intragenic deletions or duplications may also be 
considered, although intragenic deletions and duplications are rare (see Table 1).
A hereditary cancer multigene panel that includes CYLD and other genes of interest (see Differential 
Diagnosis) may also be considered. Note: (1) The genes included in the panel and the diagnostic sensitivity of 
the testing used for each gene vary by laboratory and are likely to change over time. (2) Some multigene panels 
may include genes not associated with the condition discussed in this GeneReview. (3) In some laboratories, 
panel options may include a custom laboratory-designed panel and/or custom phenotype-focused exome 
analysis that includes genes specified by the clinician. (4) Methods used in a panel may include sequence 
analysis, deletion/duplication analysis, and/or other non-sequencing-based tests.
For an introduction to multigene panels click here. More detailed information for clinicians ordering genetic 
tests can be found here.
Table 1. Molecular Genetic Testing Used in CYLD Cutaneous Syndrome
Gene 1 Method Proportion of Probands with a Pathogenic Variant 2 Detectable by Method
CYLD
Sequence analysis 3 40%-100% 4, 5, 6
Gene-targeted deletion/duplication 
analysis 7 Rare 
8
1. See Table A. Genes and Databases for chromosome locus and protein.
2. See Molecular Genetics for information on allelic variants detected in this gene.
3. Sequence analysis detects variants that are benign, likely benign, of uncertain significance, likely pathogenic, or pathogenic. 
Pathogenic variants may include small intragenic deletions/insertions and missense, nonsense, and splice site variants; typically, exon 
or whole-gene deletions/duplications are not detected. For issues to consider in interpretation of sequence analysis results, click here.
4. A single test center performing CYLD testing over a five-year period detected pathogenic CYLD variants in ∼70% of 56 probands 
who fulfilled previously published testing criteria using Sanger sequencing of coding exons [ESHG 2019].
5. In a smaller study of 25 probands, the presence of cylindromas raised the likelihood of pathogenic variant detection to between 86% 
and 100% [Saggar et al 2008].
6. In probands with only trichoepitheliomas, the rate of pathogenic variant detection was as low as 40% [Saggar et al 2008].
7. Gene-targeted deletion/duplication analysis detects intragenic deletions or duplications. Methods used may include quantitative 
PCR, long-range PCR, multiplex ligation-dependent probe amplification (MLPA), and a gene-targeted microarray designed to detect 
single-exon deletions or duplications.
8. Vanecek et al [2014] reported two affected individuals with large deletions of CYLD out of 13 affected individuals who did not 
demonstrate a pathogenic CYLD variant using Sanger sequencing.
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Clinical Characteristics
Clinical Description
CYLD cutaneous syndrome (CCS) encompasses the clinical phenotypes described in individuals with germline 
pathogenic CYLD variants. Historically descriptive names including Brooke-Spiegler syndrome (BSS), familial 
cylindromatosis (FC), and multiple familial trichoepithelioma (MFT) were assigned on the basis of the 
predominant tumor type and location; these conditions are now recognized to constitute a clinical spectrum. 
Individuals with the clinical phenotypes of BSS, FC, and MFT can all present in a single family, and the lack of 
prognostication offered by these historical labels favors the use of CYLD cutaneous syndrome as a diagnostic 
term for those with this single gene disorder.
Table 2. Features of CYLD Cutaneous Syndrome
Feature 1 # of Persons w/Feature Comment
Phenotype of predominantly
cylindromas/spiradenomas 14/26 (∼54%)
Phenotype of predominantly trichoepitheliomas 8/26 (∼30%)
Phenotype of mixed cylindroma/spiradenoma/
trichoepithelioma 4/26 (∼15%)
Severe phenotype
necessitating
complete scalp excision
6/26 (∼23%)
In a further study of a Hungarian pedigree, 2 
5/21 individuals w/a germline pathogenic CYLD 
variant had this severe phenotype.
Salivary gland tumors ~5%
Pulmonary cylindromas 3 persons 3 May result in respiratory compromise if lesion affects the large airways
Except where otherwise noted, the table summarizes a single study by Rajan et al [2009a], which analyzed the clinical features of 26 
individuals with germline pathogenic CYLD variants.
1. While by definition most individuals with CYLD cutaneous syndrome will be affected by one of more of the characteristic tumors, 
precise detail about frequency of the clinical features is lacking in most published studies.
2. Nagy et al [2013]
3. Vernon et al [1988], Brown et al [2018b]
To date, more than 100 pedigrees have been identified with a germline pathogenic variant in CYLD, most of 
whom have family-specific pathogenic variants with few mutational hot spots identified [Rajan et al 2009a, 
Grossmann et al 2013, Nagy et al 2015]. The following description of the phenotypic features associated with this 
condition is based on these reports.
CYLD cutaneous syndrome typically manifests in the second or third decade with the appearance of multiple 
skin tumors including cylindromas, spiradenomas, and trichoepitheliomas. The first tumor typically presents at 
puberty, but tumors have been reported to present in children as young as age eight years. Tumors progressively 
accumulate through adulthood. A female preponderance was reported in early studies of small pedigrees; 
however, assessment of larger pedigrees supports equal penetrance in both males and females, with increased 
expressivity in females. The presence of tumors at sites of secondary sexual hair development, the timing of 
onset, and the gender disparity in severity in females with cylindromas suggest a role of hormonal factors in 
tumor pathogenesis [Rajan et al 2009b].
Natural history studies in CYLD cutaneous syndrome are limited, but a recent study that followed three affected 
individuals with a combined total of 32 skin tumors visible on serial CT scans (6.7-23.5 mm across) showed 
progressive growth in 30 out of 32 lesions over a period of one year [Brown et al 2018b]. The progressive growth 
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of these benign tumors supports the case for considering early excision of skin lesions rather than waiting until a 
more extensive procedure is required (see Table 5). Affected individuals frequently need repeated procedures 
due to the development of new tumors and, in some cases, the recurrence of incompletely excised tumors.
Individuals with CYLD cutaneous syndrome may present with more than one tumor type discussed below.
• Tumors typically arise on the scalp and face but can also arise on the torso and sun-protected sites, such as 
the genital and axillary skin.
• Tumors are often painful and may cause sexual dysfunction when they arise on genital skin.
• Tumors arising within the ear (a favored site for tumor formation) can occlude the external auditory canal 
and result in conductive hearing loss.
• Although the tumors are usually benign, malignant transformation is recognized, and affected individuals 
should be guided to report tumors which are rapidly growing, bleeding, ulcerating, or different in 
appearance from their usual tumors.
Cylindromas
Cylindromas are well-circumscribed, smooth, pale pink nodular tumors, often with arborizing vessels visible. 
The tumors are slow growing and vary in size from a few millimeters to >5 mm (see Figure 1a). The finding of 
mixed cylindroma and spiradenoma histology within a single tumor is common in CYLD cutaneous syndrome, 
and the two terms have been used to describe variants of the same tumor [Rajan et al 2011a].
Confluent scalp tumors. In severe cases, tumors may cover most of the scalp, referred to as confluent scalp 
tumors (see Figure 1b).
• Early surgical intervention may prevent or delay confluent scalp tumors.
• One study of two families reported that confluent scalp tumors affected up to one in four individuals with 
a heterozygous germline pathogenic CYLD variant [Rajan et al 2009a].
Pulmonary cylindromas. Single or multiple pulmonary cylindromas that originate from the skin have been 
described in three individuals with CYLD cutaneous syndrome [Vernon et al 1988, Brown et al 2018b]. In these 
cases, there is no history of a primary malignant cutaneous cylindroma in the skin, lymph node disease is absent, 
and pulmonary histology is benign, leading them to be categorized as "benign" metastases.
• One individual presented at age 64 with breathlessness on exertion and was found to have multiple 
pulmonary tumors. This individual required serial monitoring with pulmonary imaging, and received 
endocopic laser ablation to maintain large airway patency.
• A second individual had four asymptomatic pulmonary tumors discovered incidentally on a chest 
radiograph at age 80 years. The tumors were histologically confirmed on autopsy.
• Whole-exome and genome sequencing have shown pulmonary cylindromas to harbor an additional 
pathogenic variant in AKT1 and a UV mutation signature confirming cutaneous origin [Davies et al 
2019].
• The true prevalence of pulmonary cylindromas in individuals with CYLD cutaneous syndrome is not 
known, as prospective radiologic imaging studies of large numbers of affected individuals have yet to be 
performed.
• Currently, there are no routine surveillance imaging guidelines that can be recommended; however 
clinicians who care for individuals with CYLD cutaneous syndrome need to be aware that these tumors do 
arise and may need to be monitored to determine rate of growth, and that surgical interventions may be 
necessary to ablate pulmonary tumors that threaten large airway patency.
Histopathology. The histologic appearance of well-circumscribed cylindrical nests of basaloid cells in the 
dermis led to the term "cylindroma." Each cluster consists of darker, basophilic cells at the periphery, and larger 
CYLD Cutaneous Syndrome 5
pale cells centrally and is surrounded by a thick, hyaline membrane consisting of extracellular matrix proteins 
(including collagen IV and VII and laminin-332) in the basement membrane of the skin (see Figure 2a).
Spiradenomas
Spiradenomas are nodular tumors that are often blue/black in color. They tend to be painful and can grow up to 
10 cm in diameter (see Figure 3).
Histopathology. Spiradenomas are relatively disorganized histologically when compared to cylindromas and 
consist of sheets of epithelial cells associated with a lymphocytic infiltrate (mixed T and B cells). Some affected 
individuals present with histologic features of both cylindroma and spiradenoma within a single tumor 
specimen, giving rise to the term spiradenocylindroma. In addition, there is evidence that histologically 
organized cylindroma and histologically disorganized spiradenoma represent extremes of a spectrum of 
histophenotype of the same tumor [Rajan et al 2011a] (see Figure 2b).
Trichoepitheliomas
Trichoepitheliomas are skin-colored papules or firm nodules, mainly found on the central face (see Figure 4). 
They are often symmetrically distributed and usually no more than 2-5 mm across.
Histopathology. Trichepitheliomas demonstrate clusters of basaloid germinative cells with keratinizing cystic 
spaces and superficial follicular differentiation surrounded by a fibrocytic stroma. Intra-stromal clefts and 
mesenchymal papillary buds may be seen.
Other Findings
Salivary lesions. Affected individuals are also at risk of developing tumors of the salivary glands, typically 
membranous basal cell adenoma (MBCA) [Jungehülsing et al 1999] usually after age 40 years.
• These tumors typically present as a lump in the parotid gland, may be bilateral, and warrant a biopsy to 
confirm the diagnosis.
• MBCA is a benign entity which may be managed surgically, but recurs in up to 25% of affected individuals 
[Zarbo 2002] (see also Malignant transformation).
Malignant transformation has been (rarely) reported in preexisting spiradenomas, cylindromas, 
spiradenocylindromas, and MBCA [Hyman et al 1988, Kazakov 2016]. Malignant tumors tend to be aggressive 
carcinomas with frequent local infiltrative growth or metastases.
• Transcalvarial invasion is uncommon, but has been observed [Serracino & Kleinschmidt-Demasters 
2013].
• Malignant metastases to bone, lung, and liver have been reported [Gerretsen et al 1993].
• Death from metastatic disease has been described in affected individuals in the early fifth decade [Kazakov 
et al 2009].
• Malignant histopathology. Four diverse histologic patterns of malignant cylindroma or spiradenoma have 
been described [Kazakov et al 2009], including:
⚬ Salivary gland type basal cell adenocarcinoma-like pattern, low-grade
⚬ Salivary gland type basal cell adenocarcinoma-like pattern, high-grade
⚬ Invasive adenocarcinoma, not otherwise specified
⚬ Sarcomatoid (metaplastic) carcinoma
Other skin lesions and malignancies
• Affected individuals may also develop small milia cysts on the skin of the face [Bajwa et al 2018].
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• Vulval cysts consisting histologically of multiple epidermal inclusion cysts and milia were reported in one 
affected female [Dubois et al 2017].
• Squamous cell carcinoma [Ganguly et al 2012, Ma et al 2016] and follicular squamous cell carcinoma 
[Dubois et al 2018] arising in individuals with CYLD cutaneous syndrome have been described in isolated 
reports.
• Basal cell carcinoma (BCC) is the most common human cancer, and coexistence in individuals with CYLD 
cutaneous syndrome may be coincidental or related to overlap in the appearance of each under the 
Figure 1. A. Cylindroma demonstrating a well-circumscribed pink nodular lesion with arborizing blood vessels visible on the surface
B. Confluent scalp cylindromas in a severely affected individual with CYLD cutaneous syndrome
Rajan & Ashworth [2015]; republished with permission of author.
Figure 2. A. Histopathology of cylindroma
B. Histopathology of spiradenoma
Rajan & Ashworth [2015]; republished with permission of author.
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microscope. However, in a recent study of a large South American family with CYLD cutaneous 
syndrome, BCC was a reported in 25% of affected family members from this kindred [Arruda et al 2019].
Segmental disease due to mosaic pathogenic CYLD variants should be considered when individuals develop 
unilateral clusters of any cylindromas, spiradenomas, or trichoepitheliomas [Arefi et al 2019]. Findings may 
include skin lesions arranged in a linear fashion [Furuichi et al 2012] following embryologic skin development 
lines (lines of Blaschko). The presentation of unilateral clusters may reflect either a pathogenic CYLD variant in 
the skin alone (late postzygotic mosaicism) or a pathogenic variant in both the blood and the skin (early 
postzygotic mosaicism) (see Figure 5 below) [Arefi et al 2019].
Genotype-Phenotype Correlations
No convincing genotype-phenotype correlations have been identified. There is a suggestion that individuals with 
pathogenic missense variants may have a milder phenotype; however, as missense variants constitute a minority 
of pathogenic variants in affected individuals (most have pathogenic truncating variants, which can also result in 
a mild phenotype), further studies are needed to investigate this hypothesis [Nagy et al 2015].
Nomenclature
Historically, descriptive names including Brooke-Spiegler syndrome (BSS), familial cylindromatosis (FC), and 
multiple familial trichoepithelioma (MFT) were assigned on the basis of the predominant tumor type and 
location. These conditions are now recognized to constitute a clinical spectrum and individuals with the clinical 
phenotypes of BSS, FC, and MFT can all present in a single family. The lack of prognostication offered by these 
historic labels favors the use of CYLD cutaneous syndrome as a diagnostic term for individuals with this single-
gene disorder.
Outdated terms previously used in the literature to refer to CYLD cutaneous syndrome include the following:
• Ancell-Spiegler cylindromas
• Dermal eccrine cylindroma
• Turban tumor syndrome (now denoted as confluent scalp tumors)
Figure 3. Spiradenoma: a well-circumscribed nodular lesion (excision specimen) with characteristic blue/black appearance
Rajan & Ashworth [2015]; republished with permission of author.
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Prevalence
The true prevalence of CYLD cutaneous syndrome is unknown but may be in the order of more than 1:100,000 
population [Rajan & Ashworth 2015].
Genetically Related (Allelic) Disorders
No phenotypes other than those discussed in this GeneReview are known to be associated with germline 
pathogenic variants in CYLD.
Sporadic cylindroma and spiradenoma occurring as single tumors in the absence of any other findings of CYLD 
cutaneous syndrome frequently harbor somatic variants in CYLD that are not present in the germline [Bignell et 
al 2000, Rashid et al 2019]. Predisposition to such tumors (i.e., a single lesion, typically appearing later in life) is 
not heritable. For more information see Cancer and Benign Tumors.
Figure 4. Trichoepithelioma: small skin-colored papules with a predilection for the central face
Rajan & Ashworth [2015]; republished with permission of author.
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Differential Diagnosis
Disorders with multiple facial papules in the differential diagnosis of CYLD cutaneous syndrome (CCS) are 
summarized in Table 3.
Table 3. Disorders with Multiple Facial Papules in the Differential Diagnosis of CYLD Cutaneous Syndrome (CCS)
Gene(s) Disorder 1 Distinguishing Histologic Features in Differential Disorder Comment
FLCN Birt-Hogg-Dubé syndrome Fibrofolliculomas
NF1 Neurofibromatosis 1 (NF1) Neurofibromas Both NF1 & CCS are assoc w/lesions on the torso
Figure 5. Mosaic presentations of CYLD cutaneous syndrome
Arefi et al [2019]; published under Creative Commons license.
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Table 3. continued from previous page.
Gene(s) Disorder 1 Distinguishing Histologic Features in Differential Disorder Comment
PTEN Cowden syndrome (see PTEN Hamartoma Tumor Syndrome) Trichilemmomas
TSC1
TSC2 Tuberous sclerosis complex Angiofibromas
HR Marie Unna hypotrichosis 1 (MUHH1) (OMIM 146550) Trichoepitheliomas 
2
Severe hair breakage/loss & absence of 
cylindromas in MUHH1 further 
distinguishes MUHH1 from CCS.
PTCH1 Basal cell nevus syndrome Basal cell nevi Macrocephaly, broad nasal root & jaw cysts
Unknown Multiple syringomas (OMIM 186600) Syringomas
1. All of the disorders listed are inherited in an autosomal dominant manner.
2. Huang et al [2019]
Pilar (trichilemmal) cysts. Pilar cysts are common keratin-filled cysts that often affect the scalp in multiple 
numbers, either sporadically or inherited as an autosomal dominant trait associated with heterozygous variants 
in PLCD1 [Hörer et al 2019]. They may mimic scalp cylindromas, but clinically, the skin overlying these scalp 
lesions is normal, while in cylindromas there is frequently loss of overlying hair and thinning of the skin, giving 
it a pink translucent appearance.
Management
Evaluations Following Initial Diagnosis
To establish the extent of disease and needs in an individual diagnosed with CYLD cutaneous syndrome (CCS), 
the evaluations summarized in Table 4 (if not performed as part of the evaluation that led to the diagnosis) are 
recommended.
Table 4. Recommended Evaluations Following Initial Diagnosis in Individuals with CYLD Cutaneous Syndrome
System/Concern Evaluation Comment
Skin
Skin examination by dermatologist
• Full skin examination incl skin of the genitalia
• Painful tumors should be identified & prioritized for excision (see 
Table 5).
• Education about signs & symptoms of malignant transformation 1
Histologic examination Of tumors that are rapidly growing, have a distinct appearance, or are ulcerated or bleeding
Imaging, if clinically indicated
• Routine imaging not currently recommended
• If malignant transformation is suspected in a scalp tumor, consider 
radiologic imaging (preferably MRI), given the possibility of 
intracranial invasion.
• Little evidence is available as to when staging imaging should be 
considered for malignant tumors; consult specialist skin cancer 
multidisciplinary team. 2
Ears/Hearing Evaluation of external auditory canals w/otoscope
• To screen for tumors that occlude the external auditory canal
• When present, clinical assessment for conductive hearing loss may 
be considered.
Oral Clinical exam of parotid glands To screen for salivary lesions
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Table 4. continued from previous page.
System/Concern Evaluation Comment
Respiratory
Assessment for signs of respiratory 
compromise in those w/new onset of 
shortness of breath, cough, or stridor
If present, radiologic imaging may be necessary to evaluate for pulmonary 
lesions.
Genetic
counseling
Consultation w/clinical geneticist &/or 
genetic counselor To incl genetic counseling & cascade testing where needed
1. Including tumors that are rapidly growing, bleeding, ulcerating or appear different than an affected individual's usual tumors.
2. This team typically includes a dermatologist, plastic surgeon, radiologist, oncologist and pathologist, all of whom can guide a 
consensus decision making process.
Treatment of Manifestations
Table 5. Treatment of Manifestations in Individuals with CYLD Cutaneous Syndrome
Manifestation/
Concern Treatment Considerations/Other
Cylindroma, spiradenoma, 
trichoepithelioma
Removal of tumors by 
conventional surgery
• Repeated surgical procedures to ↓ tumor burden 
typically required 1,2
• "Scalp-sparing" strategies incl early primary 
excision, tumor enucleation, & excision followed by 
secondary intention healing techniques 
recommended; 3 avoid removing large areas of scalp.
• Complete scalp excision to be used only when no 
feasible alternatives 4
Hyfrecation For selected small tumors, such as trichoepithelioma on the nasolabial skin 5
Laser
• Ablative laser resurfacing of smaller lesions (i.e., 
perinasal trichoepitheliomas) can yield good 
cosmetic results. 6
• However, the advantage of laser treatment for large 
cylindromas & spiradenomas over standard excision 
is not clear. Laser treatment also precludes histologic 
assessment.
Mohs micrographic surgery 7
• Technique allows dermatologic surgeon to track 
invasive tumor cells & confirm histologic clearance 
before closing the skin defect. 8
• Mohs may be of limited benefit in CCS, as it may be 
difficult to obtain tumor-negative margins, leading 
to large defects.
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Table 5. continued from previous page.
Manifestation/
Concern Treatment Considerations/Other
Malignant tumors
Multidisciplinary team input 
required to develop management 
plan
• At least 8 different types of malignant tumors are 
seen in affected individuals; w/the exception of BCC, 
these would be considered rare cancers & require 
appropriate evaluation following histopathologic 
assessment (see Clinical Characteristics).
• Each case may need to be assessed & staged; 
decision should be made by a skin cancer 
multidisciplinary team w/support from 
dermatologists, oncologists, pathologists, plastic 
surgeons, & radiologists.
BCC = basal cell carcinoma; CCS = CYLD cutaneous syndrome
1. Tumors progressively grow over time such that early treatment may reduce the need for extensive surgical procedures and also allow 
for the use of local anesthetic.
2. Benign lesions removed for cosmetic reasons should have narrow margins to leave as much normal healthy tissue as possible.
3. Rajan et al [2009b], Brass et al [2014]
4. Complete scalp excision is not curative. Often tumors develop from follicles within the graft, and individuals can have significant 
tumors at other sites, such as on the trunk.
5. Histologic assessment of a representative lesion may be useful prior to ablative procedures. If there is a clinical suspicion of basal cell 
carcinoma, a biopsy should be performed prior to initiating ablative procedures.
6. Repeated treatments are often needed and may not be cost effective.
7. This technique has been used to treat sporadic cylindroma and spiradenoma where recurrence has occurred after primary surgical 
excision.
8. Mohs may be best reserved for sporadic cases.
Prevention of Primary Manifestations
The role of UV light in the pathogenesis of the tumors seen in CYLD cutaneous syndrome is unclear. As with all 
skin cancer predisposition syndromes, appropriate precautions against UV-related skin damage are 
recommended [Davies et al 2019].
Surveillance
It is recommended that individuals with CYLD cutaneous syndrome undergo at least annual full skin 
examination by a dermatologist, with some affected individuals requiring skin review every three to four 
months.
• An assessment of tumor burden and rate of new tumor development can be made, and existing tumors 
can also be monitored for any signs of malignant transformation.
• Annual monitoring will guide the frequency and interval of surgical procedures.
• Between appointments, affected individuals should be asked to report growing, ulcerated, or bleeding 
tumors or tumors that appear different from existing lesions so that they can be assessed to determine if 
urgent excision is warranted.
Agents/Circumstances to Avoid
Radiotherapy should be avoided as it causes DNA damage and may result in further tumor formation or 
malignant transformation of existing lesions [Crain & Helwig 1961, Rajan & Ashworth 2015].
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Evaluation of Relatives at Risk
It is appropriate to clarify the genetic status of apparently asymptomatic older and younger at-risk relatives of an 
affected individual in order to identify as early as possible those who would benefit from prompt initiation of 
treatment and preventive measures.
See Genetic Counseling for issues related to testing of at-risk relatives for genetic counseling purposes.
Therapies Under Investigation
Treatment for CYLD cutaneous syndrome is largely surgical. The first placebo-controlled early-phase trial of a 
topical targeted kinase inhibitor (tropomyosin receptor kinase) showed short-term safety [Danilenko et al 2018]; 
a dose escalation study is needed to determine efficacy.
It is important to recognize that tumors in CYLD cutaneous syndrome lack a curative medical therapy, and any 
treatments will likely need to be repeated over the affected individual's lifetime. Isolated case reports of topical or 
intralesional therapeutic interventions must be interpreted with caution as all have some or all of the following 
limitations:
• They are not placebo controlled.
• No objective measures were used to assess improvement.
• Only short-term follow-up data are presented.
• No long-term safety data regarding the repeated use of these agents in treatment of CYLD cutaneous 
syndrome are available.
Search ClinicalTrials.gov in the US and EU Clinical Trials Register in Europe for access to information on 
clinical studies for a wide range of diseases and conditions.
Genetic Counseling
Genetic counseling is the process of providing individuals and families with information on the nature, inheritance, 
and implications of genetic disorders to help them make informed medical and personal decisions. The following 
section deals with genetic risk assessment and the use of family history and genetic testing to clarify genetic status for 
family members. This section is not meant to address all personal, cultural, or ethical issues that individuals may 
face or to substitute for consultation with a genetics professional. —ED.
Mode of Inheritance
CYLD cutaneous syndrome (CCS) is inherited in an autosomal dominant manner.
Risk to Family Members
Parents of a proband
• Most individuals diagnosed with CYLD cutaneous syndrome have an affected parent. Because the degree 
of severity can vary within families, a mildly affected parent may have a more severely affected child and 
vice versa.
• Some individuals diagnosed with CYLD cutaneous syndrome have the disorder as the result of a de novo 
CYLD pathogenic variant. Simplex cases (i.e., a single occurrence in a family) have not been evaluated 
sufficiently to determine if the pathogenic variant occurred de novo, and thus the proportion of CYLD 
cutaneous syndrome caused by a de novo pathogenic variant is unknown.
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• Molecular genetic testing is recommended for the parents of a proband with an apparent de novo 
pathogenic variant.
• If the pathogenic variant found in the proband cannot be detected in the leukocyte DNA of either parent, 
possible explanations include a de novo pathogenic variant in the proband or somatic and/or germline 
mosaicism in a parent.* One instance of a proband inheriting a pathogenic variant from a parent with 
germline mosaicism has been reported [Arefi et al 2019].
* Misattributed parentage can also be explored as an alternative explanation for an apparent de novo 
pathogenic variant.
• The family history of some individuals diagnosed with CYLD cutaneous syndrome may appear to be 
negative because of failure to recognize the disorder in family members, a mild phenotype, early death of 
the parent before the onset of symptoms, or late onset of the disease in the affected parent. Therefore, an 
apparently negative family history cannot be confirmed unless molecular genetic testing has been 
performed on the parents of the proband.
Note: If the parent is the individual in whom the pathogenic variant first occurred, s/he may have somatic 
mosaicism for the variant and may be minimally affected. Such individuals may present with a unilateral 
cluster of cylindromas, spiradenomas, or trichoepitheliomas
Sibs of a proband. The risk to the sibs of the proband depends on the clinical/genetic status of the proband's 
parents:
• If a parent of the proband is affected and/or is known to be heterozygous for the pathogenic variant 
identified in the proband, the risk to the sibs is 50%. Although the penetrance of CYLD cutaneous 
syndrome approaches 100%, clinical severity as well as the pattern of presentation of the tumors (e.g., on 
the scalp vs the face) and tumor types may vary among heterozygous sibs.
• If the proband has a known CYLD pathogenic variant that cannot be detected in the leukocyte DNA of 
either parent and both parents are clinically unaffected, the recurrence risk to sibs is slightly greater than 
that of the general population because of the possibility of parental germline mosaicism.
• If clinical evaluation of a parent suggests a mosaic presentation of CYLD cutaneous syndrome and 
molecular genetic testing is consistent with postzygotic mutation of CYLD in the parent, the risk to sibs is 
variable but is presumed to be less than 50% [Arefi et al 2019] (see Figure 5).
Offspring of a proband. Each child of an individual with a heterozygous CYLD pathogenic variant has a 50% 
chance of inheriting the pathogenic variant. Because intrafamilial clinical variability is observed in CYLD 
cutaneous syndrome, offspring who inherit a CYLD pathogenic variant may be more or less severely affected 
than the transmitting parent.
Other family members. The risk to other family members depends on the status of the proband's parents: if a 
parent has a CYLD pathogenic variant, his or her family members may be at risk.
Related Genetic Counseling Issues
See Management, Evaluation of Relatives at Risk for information on evaluating at-risk relatives for the purpose 
of early diagnosis and treatment.
Predictive testing for at-risk asymptomatic adult family members requires prior identification of the CYLD 
pathogenic variant in the family.
Family planning
• The optimal time for determination of genetic risk and discussion of the availability of prenatal testing is 
before pregnancy.
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• It is appropriate to offer genetic counseling (including discussion of potential risks to offspring and 
reproductive options) to young adults who are affected or at risk.
DNA banking is the storage of DNA (typically extracted from white blood cells) for possible future use. Because 
it is likely that testing methodology and our understanding of genes, allelic variants, and diseases will improve in 
the future, consideration should be given to banking DNA of affected individuals.
Prenatal Testing and Preimplantation Genetic Testing
Once the CYLD pathogenic variant has been identified in an affected family member, prenatal testing for a 
pregnancy at increased risk and preimplantation genetic testing are possible.
Differences in perspective may exist among medical professionals and within families regarding the use of 
prenatal testing, particularly if the testing is being considered for the purpose of pregnancy termination rather 
than early diagnosis. While most centers would consider use of prenatal testing to be a personal decision, 
discussion of these issues may be helpful.
Resources
GeneReviews staff has selected the following disease-specific and/or umbrella support organizations and/or registries 
for the benefit of individuals with this disorder and their families. GeneReviews is not responsible for the 
information provided by other organizations. For information on selection criteria, click here.
• DermNet NZ
New Zealand
Brooke-Spiegler syndrome
• National Library of Medicine Genetics Home Reference
Brooke-Spiegler syndrome
Molecular Genetics
Information in the Molecular Genetics and OMIM tables may differ from that elsewhere in the GeneReview: tables 
may contain more recent information. —ED.
Table A. CYLD Cutaneous Syndrome: Genes and Databases
Gene Chromosome Locus Protein Locus-Specific 
Databases
HGMD ClinVar
CYLD 16q12.1 Ubiquitin carboxyl-
terminal hydrolase 
CYLD
CYLD database CYLD CYLD
Data are compiled from the following standard references: gene from HGNC; chromosome locus from OMIM; protein from UniProt. 
For a description of databases (Locus Specific, HGMD, ClinVar) to which links are provided, click here.
Table B. OMIM Entries for CYLD Cutaneous Syndrome (View All in OMIM)
132700 CYLINDROMATOSIS, FAMILIAL
601606 TRICHOEPITHELIOMA, MULTIPLE FAMILIAL, 1
605018 CYLD LYSINE-63 DEUBIQUITINASE; CYLD
605041 BROOKE-SPIEGLER SYNDROME; BRSS
16 GeneReviews®
Molecular Pathogenesis
CYLD encodes the tumor suppressor ubiquitin carboxyl-terminal hydrolase, an enzyme involved in the 
deubiquitination of "Lys-63" (K63) [Brummelkamp et al 2003, Trompouki et al 2003] and "Met-1" linked 
ubiquitin chains [Draber et al 2015, Kupka et al 2016]. CYLD negatively regulates NF-κB by removing Lys-63 
linked ubiquitin chains from TRAF2, TRAF6, and NEMO, thus tempering the activity of NF-κB. In addition, 
CYLD deubiquitinates other substrates within the NF-κB signaling pathway, such as BCL3 and TAK1. In CYLD 
cutaneous syndrome tumors, CYLD is lost, and the consequently increased NF-κB signaling may give tumor 
cells a survival advantage via proliferation and resistance to apoptosis.
CYLD also negatively regulates a range of signaling pathways that are important in inflammation and cancer, 
including JNK, Wnt, TGFB1, and Notch [Rajan & Ashworth 2015]. Transcriptome studies of cylindromas and 
spiradenomas demonstrate evidence of increased NF-κB and Wnt signaling [Rajan et al 2011a, Rajan et al 
2011b].
Mechanism of disease causation. As is the case for many tumor predisposition syndromes, CYLD cutaneous 
syndrome occurs through a loss-of-function mechanism that requires a somatic "second hit" for disease 
manifestation. In CYLD cutaneous syndrome tumors, loss of the remaining normal allele is frequently seen (loss 
of heterozygosity), either by reduplication of the entire arm of 16q harboring the germline pathogenic variant, or 
by a second pathogenic variant in the remaining normal allele. Recent work has suggested that recurrent 
pathogenic variants in DNMT3A and BCOR may also occur in addition to biallelic CYLD loss, suggesting that 
epigenetic dysregulation may contribute to tumor pathogenesis [Davies et al 2019].
CYLD-specific laboratory technical considerations. For mosaic cases, it may be necessary to study tumor 
tissue from multiple skin samples. This can be technically challenging on FFPE tissue; if possible, fresh skin 
biopsy tissue should be used for DNA extraction.
Cancer and Benign Tumors
Somatic CYLD pathogenic variants have been found in sporadic cylindromas and spiradenomas [Bignell et al 
2000]. They have also been found in salivary gland tumors such as basal cell adenocarcinoma [Rito et al 2018] 
and adenoid cystic carcinoma [Stephens et al 2013]. In hematologic malignancies, there are reports of CYLD 
deletion playing a role in myeloma, where a recurrent contiguous deletion involving CYLD and WWOX is noted 
to be associated with a worse prognostic outcome [Jenner et al 2007]. CYLD pathogenic variants have been 
reported in an isolated case of Hodgkin lymphoma [Schmidt et al 2010].
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